These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent. Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836 [TBL] [Abstract][Full Text] [Related]
12. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice. Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847 [TBL] [Abstract][Full Text] [Related]
13. Identification of progenitor cells that contribute to heterotopic skeletogenesis. Lounev VY; Ramachandran R; Wosczyna MN; Yamamoto M; Maidment AD; Shore EM; Glaser DL; Goldhamer DJ; Kaplan FS J Bone Joint Surg Am; 2009 Mar; 91(3):652-63. PubMed ID: 19255227 [TBL] [Abstract][Full Text] [Related]
14. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva. Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586 [TBL] [Abstract][Full Text] [Related]